Because of ontogenic influences on the pathophysiologic mechanisms of brain injury in the perinatal brain, and in particular, the incomplete development of adenosine receptor systems, we investigated the potential for adenosine to provide cerebroprotection in a well established newborn rat model of hypoxiaischemia. Fifteen litters of postnatal d 7 animals were subjected to unilateral carotid ligation and exposure to hypoxia (8% oxygen) for 3 h. Immediately after hypoxia-ischemia, animals received either the adenosine deaminase inhibitor deoxycoformycin (DCF; 2.5 mg/kg intraperitoneally) or the adenosine uptake inhibitor propentofylline (PPF; 10 mg/kg intraperitoneally); paired littermates received an equivalent volume of normal saline. On postnatal d 14, injury or protection was assessed by differences in hemispheric weights, morphometric determinations of infarct area, and histopathologic analyses. DCF resulted in a 34% (p = 0.02) and 31% ( p = 0.03) reduction in hemispheric weight disparities and infarct area, respectively; for PPF, these reductions were 46% ( p = 0.03) and 32% ( p = 0.04), Although the brain of the newborn exhibits a higher tolerance to ischemia than that of the adult, morbidity and mortality from hypoxic-ischemic encephalopathy in the perinatal period remain high (1). Although the general pathophysiologic mechanisms underlying cerebral ischemic injury are probably similar between age groups, the unique characteristics of energy and glucose metabolism (2), glutamate receptor physiology (3, 4), and vascular regulation (5, 6) in the newborn brain may dictate separate therapeutic regimens for affected neonates relative to adults.
respectively. Light microscopic examinations of striatum, thalamus, hippocampus, and cortex revealed that both drugs significantly improved histologic scores as well. Measurements in six separate litters indicated that neither drug significantly reduced core body temperature for at least 6 h postadministration. These findings indicate that potentiation of endogenous adenosine levels in the perinatal brain can significantly ameliorate brain injury. Each of these treatment strategies was effective even when administered after the hypoxic-ischemic insult. Thus, further investigations of adenosinergic therapies are warranted in this and other perinatal models of cerebral ischemia to elucidate in detail their potential for clinical application. (Pediatr Res 38: 306-311, 1995) Abbreviations DCF, deoxycoformycin PPF, propentofylline NMDA, N-methyl-D-aspartate cerebral ischemia (see Ref. 7 for review), and the mechanistic basis for such an adenosine-mediated reduction in ischemic brain injury has been outlined (8) . Ontogenic studies of the brains of fetal and newborn animals indicate that the requisite metabolic enzymes and transporters for adenosine are fully matured at birth or earlier (9) (10) (11) (12) . There is also consistent evidence that cerebral adenosine production increases in response to perinatal hypoxia-ischemia (13) (14) (15) (16) . Although cerebral vessels in fetal and newborn animals exhibit the characteristic vasodilatative response to adenosine (17, 18) , significant development of neuronal adenosine receptors, particularly in terms of density and coupling to second messengers, may occur postnatally (12, 19, 20) . Thus, adenosinebased treatments may not provide therapeutic efficacy against cerebral hypoxia-ischemia in the perinatal period. To address this possibility, we used two different drugs to determine whether potentiating endogenous adenosine would confer cerebroprotection in a neonatal model of hypoxia-ischemia.
METHODS
Experimental model. The well characterized Rice-Vannucci model of perinatal hypoxia-ischemia was used (21) , wherein unilateral brain injury is induced by a combination of unilateral carotid ligation and exposure to hypoxia. Briefly, 15 litters of postnatal d 7 Sprague-Dawley rat pups were anesthetized with halothane, and their left carotid artery was ligated, cauterized, and cut to ensure permanent blood flow interruption; incisions were closed with cyanoacrylate. The entire surgical procedure was typically completed in less than 5 min. Pups were allowed to recover in a warm environment for 15 min before their return to the dam. Ninety minutes after ligating the carotid of the last littermate, the pups were exposed to 3 h of normothermic hypoxia (8% oxygen). Six interconnected Plexiglas chambers (440 m~~) submerged in water warmed to 36.0°C were used; each chamber held either one or two animals, and received prewarmed hypoxic gas at 100 mmymin.
Drug treatments. Within 5-10 min of return to normoxia, half the pups of each litter received a single dose of either DCF (pentostatin; 2.5 mg/kg intraperitoneally; Parke-Davis, Ann Arbor, MI), which inhibits brain adenosine deaminase (22) , or PPF (HWA 285; 10 mglkg intraperitoneally; Hoechst, Wiesbaden, Germany), which inhibits reuptake of extracellular adenosine (23) . The animals were then returned to the dam and monitored for 30-60 min to be sure that no pup was left untended by the dam. Pups were reared under normal conditions until postnatal d 14, when injury analyses were undertaken. Seven pups from the 8 DCF litters and 12 pups from the 7 PPF litters were used as nonligated, nonhypoxic controls, and were also killed at postnatal d 14.
In six separate litters, we assessed the protective effects of MK-801, the noncompetitive NMDA receptor antagonist. As in the DCF-and PPF-treated animals, MK-801 (3 mglkg, intraperitoneally) was administered as a single dose immediately after the hypoxic period was terminated. Hemispheric weight analyses were performed 1 wk later.
In another six litters, rectal temperatures were obtained under baseline conditions and at 0.5, 1, 2, 4, and 6 h after intraperitoneal administration of DCF or PPF to determine whether these compounds caused a significant hypothermia. In these studies, each litter was divided equally, with half receiving either DCF or PPF, and half receiving saline vehicle. Animals were returned to the dam after the injections and removed thereafter as necessary for the rapid assessment of core body temperature.
Quantification of injury or neuroprotection. Injury was assessed by criteria previously established for this model (24, 25) , which included a combination of hemispheric weight measurements, determinations of infarct area, and histopathologic analyses. In brief, postnatal d 14 animals were killed by decapitation secondary to halothane overdose, and their brains were removed and placed in chilled saline. The cerebellum was removed, as well as the olfactory lobes; the forebrain was then sectioned at the midline; left and right hemispheric weights to the nearest 0.1 mg were obtained. The hemispheres were then realigned and frozen together on aluminum foil in contact with a sheet of dry ice. Ten-micron thick coronal sections were obtained and Nissl-stained (methylene bluelazure 11).
In the majority of animals from the DCF experiments, and in more than half the animals from the PPIi experiments, relative infarct area was determined by bilateral rnorphometric analyses of hemispheric cross-sectional area in coronal sections from two different anteroposterior levels (the dorsal hippocampus and the striatum) using an image analysis system (Optimas; Bioscan, Inc., Edmonds, WA). Infarct area was measured in at least three consecutive coronal sections for each level, and the average change in infarct area at these two anteroposterior levels is reported herein. Alterations in neuronal morphology were assessed by light microscopy at 40X in three adjacent coronal sections. Neurons in the caudate putamen and neurons in the lateral cortex were examined at the level of the striatum (anterior). Hippocampal subfields, and neurons of the medial, lateral, and ventral thalamus were examined at the level of the dorsal hippocampus (posterior). The extent of alterations in neuronal morphology, ranging from pyknotic nuclei to necrosis to frank infarction, was scored for each region by a blind observer using the following 5-point semiquantitative scale: 0 -no neurons injured; 1 = mild injury; 2 == moderate injury with some necrotic neurons; 3 --severe injury with widespread necrosis; 4 = complete infarction. Cerebral hypoxicischemic injury in the MK-801-treated litters was assessed only by hemispheric weight comparisons.
Statistical analyses.
All data are shown as mean + SEM.
Comparisons of hemispheric weights, infarct areas, and rectal temperatures between drug-treated and vehicle-treated groups were by unpaired t tests. The nonpara.metric Mann-Whitney test was used to determine significance for the regional and composite histopathologic scores. Linear regression was performed to determine the extent of correlation between reduction in hemispheric weight and reduction in infarct volume. A p value less than 0.05 was considered significant.
RESULTS

DCF-treated animals.
Animals that received the adenosine deaminase inhibitor DCF after hypoxia-ischemia exhibited significantly less brain injury relative to vehicle-treated littermates. In the eight litters used to assess the cerebroprotective effects of DCF, the 25 vehicle-treated animals showed a 29 -t 3% reduction in hemispheric weights, whereas only a 19 + 3% reduction in hemispheric weights was noted in the 26 DCFtreated animals (Fig. 1) . By this criterion, a 34% reduction in injury ( p = 0.02) was achieved by DCF. In the 20 vehicletreated and 22 DCF-treated animals from the above groups that were used for morphometric analyses, 29 ? 3% and 20 + 3% reductions in hemispheric area ipsilateral to the carotid ligation were measured, respectively, reflecting a 31% reduction ( p = 0.03) in infarct area by DCF. These changes in infarct area were highly correlated ( r = 0.89; p < 0.001) to the changes in hemispheric weights measured in these same brains (Fig. 2) . DCF treatment did not cause hypothermia (Table 1) .
Regional histopathologic analyses indicated that DCF reduced the severity of neuronal injury across several regions (Table 2 ). Significant improvements in neuronal injury scores shown as relative frequency distribution histograms of neuronal injury, based on the following semiquantitative scale: 0 = no neurons injurcd; 1 = mild injury; 2 = moderate injury with some necrotic neurons; 3 --severe injury with widespread necrosis; 4 = complete infarction. Regional scores in striatum, hippocampal dentate, CAI, CA3, and CA4, thalamus, and cortex (Table  2) were averaged to provide the composite frequency shown for DCF-and vehicle-treated groups. The mean histopathologic injury score for DCF-treated animals (1.49 5 0.11) was significantly lower ( p < 0.0001; Mann-Whitney) than that measured in vehicle-treated littermates (2.39 i 0.12).
suggest that adenosine-induced reductions in ischemic injury may also derive in part from adenosine's attenuation of free radical production by neutrophils (39) and its augmentation of endogenous antioxidant enzyme activity (40) . These neuroprotective actions depend on a reasonably well developed adenosinergic system in the perinatal brain. That hypoxia and ischemia induce prominent increases in cerebral adenosine levels in several neonatal models (13) (14) (15) (16) , and 5'-nucleotidase activity has been measured (10, 41) , indicate that the synthetic enzymes for adenosine production from AMP are developed early. Of particular relevance to the present study is the ontogeny of adenosine deaminase and adenosine
transporters, which are the respective sites of action for DCF and PPF. Adenosine deaminase activity reaches term levels midway through gestation in guinea pigs (10) and activity in newborn rats is higher than adults (1 1); adenosine transporters are present in postnatal d 6 rats at adult levels (12) or higher (9) . Therefore, the enzyme and transporter responsible for terminating the action of extracellular adenosine are functionally developed in the brain of the newborn and available for pharmacologic inhibition. However, obtaining effects of extracellular adenosine secondary to DCF-and PPF-mediated inhibition of these metabolic pathways requires the subsequent activation of adenosine receptors in several cell types. Studies of the ontogenic profile of the A , adenosine receptor in the rat indicate that, although the receptor is present at birth, adult levels of receptor density are not achieved until at least 3 wk of age (19, 20) . Furthermore, although receptor affinity does not change with postnatal development (19, 42) , receptor coupling to G proteins may be weaker in the postnatal period (26) . Less information is available regarding the ontogenesis of A, adenosine receptors, but it has been reported that a similar delay in expression is not observed (42) ; in fact, the affinity of striatal A, receptors in postnatal d 9 rats is twice that found in adults (42) . Given that cerebroarteriolar smooth muscle relaxation can be demonstrated at birth and earlier (17, 18) , vascular A, adenosine receptors appear fully developed at term as well. Thus, available evidence suggests that A, receptor-mediated effects of adenosine, such as inhibition of platelet aggregation, neutrophil-free radical release, astrocytic glycogenolysis, and vasodilation can be realized in the newborn brain in response to potentiation of extracellular adenosine levels. However, these studies also suggest that the extent of glutamate and dopamine release inhibition, hyperpolarization, glucose uptake potentiation, reduction in NMDA-mediated nitric oxide production, and other A, receptor-mediated effects of adenosine may not be as profound in the perinatal period. Given our present finding that adenosine potentiation did afford significant cerebro-protection in this model, we speculate that some of these beneficial A, receptor-mediated actions contributed to the reduction in injury we observed; definitive evidence of these particular actions, however, must await further study.
We attribute the cerebroprotective effects of DCF and PPF in the present study to potentiation of ischemia-induced increases in extracellular adenosine. Considerable in vitro evidence and data from adult animal studies support this contention. Intraperitoneal administration of 1 mg/kg DCF inhibits brain adenosine deaminase >98% (22) , and subsequent increases in ischemia-evoked release of adenosine (43) have been documented. When administered preischemically, DCF (0.5 mg/kg) afforded protection in rat (44) and gerbil (45) cerebral ischemia models. Our study is the first to show a reduction in ischemic injury with DCF when administered after the ischemic insult. By inhibiting the catabolism of adenosine, DCF may also reduce the production of oxygen free radicals via the xanthine oxidase pathway, and conserve adenosine for direct resynthesis of ATP (44) .
The cerebroprotective actions of PPF have recently been reviewed (46) . The ability of PPF to reduce ischemia-induced glutamate release (47) and increase ischemia-induced extracellular adenosine levels secondary to inhibition of adenosine transport has been demonstrated in vitro (23, 48) and in vivo (47) . Evidence of reduction in hippocampal injury, including the amelioration of calcium influx, neuronal degeneration, and astroglial edema, has been documented in pretreated gerbils (49, 50) . Our finding of a significant improvement in outcome with postischemic administration is consistent with the reductions in hippocampal injury (51) , edema (52, 53) , and superoxide production (52) , and the accelerated energy recovery (53) achieved with similar posttreatment regimens in adult animals. In acute human stroke, PPF posttreatment increased cerebral energy metabolism (54) . Additional protective actions of PPF may include a decrease in production of oxygen free radicals by activated microglia (55) , and a potentiation of A, adenosine receptor-mediated actions secondary to phosphodiesterase inhibition (46) .
The extent of cerebroprotection we observed with DCF and PPF (34-46% reduction in injury) was comparable to that we obtained in the same model with a single postischemic dose of MK-801, the noncompetitive NMDA receptor antagonist. Because it is now clear that this prototypical glutamate receptor antagonist exhibits neurotoxic side effects (56) , other potential neuroprotective agents for cerebral neuroprotection have garnered more attention. We also demonstrated that protection in our mode1 was not the result of drug-induced hypothermia. Although peripheral administration of adenosine and adenosine agonists can cause hypotension and bradycardia, potentially limiting their clinical usefulness, studies in adult animals indicate that peripheral administration of 0.5 mglkg DCF (43), and 2.5 rng/kg PPF in gerbils (53) to 10 mglkg PPF in piglets (our unpublished observations), are without effect on blood pressure. The potential therapeutic utility of DCF and PPF is also underscored by the observations that the potentiation of adenosine action is event-and site-specific (43, 47) , occurring only where ischemia already evoked an increase in its extracellular concentration.
In summary, significant cerebroprotection was demonstrated in the newborn rat by potentiation of endogenous extracellular adenosine levels. A single postischemic intraperitoneal dose of either the adenosine deaminase inhibitor DCF, or the adenosine transport inhibitor PPF, was neuroprotective in this model. Although adenosine receptor maturation may be incomplete in the newborn brain, augmenting extracellular adenosine levels by DCF and PPF still afforded protection. We conclude that adenosinergic therapy may hold promise for brain protection in infants suffering from asphyxia, cardiac arrest, and other forms of cerebral hypoxia-ischemia.
